Scalper1 News
Big biotechs Amgen (AMGN) and Regeneron Pharmaceuticals (REGN) were trading up Wednesday morning after pharmacy-benefit manager Express Scripts (ESRX) said late Tuesday that it will include both their new cholesterol-busting drugs on its 2016 preferred formulary. Express Scripts had long been saying it would make an effort to keep down the prices of Amgen’s Repatha and Regeneron’s Praluent, both of which are PCSK9 inhibitors that launched this Scalper1 News
Scalper1 News